MLYS
insider transactionsMineralys Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-165.7K
0 buy · 165.7K sell
Net value · 90d
-$4.4M
$0 in · $4.4M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
18
0 buy · 165.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
417 sh
Own +13%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
4.2K sh
Own +5%
-
Sell·S
Chief Medical Officer · 10b5-1
$114.6K
4.6K sh · $25.00
Own -7%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.4K
417 sh · $15.44
Own +1%
-
Exercise·M
Chief Medical Officer · 10b5-1
$59.4K
4.2K sh · $14.25
Own +7%
-
Exercise·M
Director · 10b5-1
$0
3.0K sh
Own +9%
-
Sell·S
Director · 10b5-1
$75.0K
3.0K sh · $25.00
Own -33%
-
Exercise·M
Director · 10b5-1
$36.1K
3.0K sh · $12.02
Own +48%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
3.5K sh
Own +3%
-
Sell·S
Chief Medical Officer · 10b5-1
$235.5K
9.9K sh · $23.81
Own -15%
-
Exercise·M
Chief Medical Officer · 10b5-1
$36.1K
3.5K sh · $10.20
Own +6%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
6.3K sh
Own New
-
Sell·S
Chief Medical Officer · 10b5-1
$151.9K
6.3K sh · $23.93
Own -9%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.9K
6.3K sh · $1.08
Own +10%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
2.2K sh
Own +14%
-
Sell·S
Chief Medical Officer · 10b5-1
$54.2K
2.2K sh · $25.00
Own -3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$34.7K
2.2K sh · $16.00
Own +3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
417 sh
Own +11%
-
Sell·S
Chief Medical Officer · 10b5-1
$11.5K
417 sh · $27.55
Own -1%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.4K
417 sh · $15.44
Own +1%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
4.2K sh
Own +5%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
3.5K sh
Own +3%
-
Sell·S
Chief Medical Officer · 10b5-1
$401.8K
14.1K sh · $28.58
Own -18%
-
Exercise·M
Chief Medical Officer · 10b5-1
$59.4K
4.2K sh · $14.25
Own +6%
-
Exercise·M
Chief Medical Officer · 10b5-1
$36.1K
3.5K sh · $10.20
Own +5%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
6.3K sh
Own +100%
-
Sell·S
Chief Medical Officer · 10b5-1
$186.3K
6.3K sh · $29.36
Own -8%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.9K
6.3K sh · $1.08
Own +9%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
2.2K sh
Own +13%
-
Sell·S
Chief Medical Officer · 10b5-1
$64.5K
2.2K sh · $29.71
Own -3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$34.7K
2.2K sh · $16.00
Own +3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
416 sh
Own +10%
-
Sell·S
Chief Medical Officer · 10b5-1
$13.0K
416 sh · $31.33
Own -1%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.4K
416 sh · $15.44
Own +1%
-
Sell·S
Chief Medical Officer · 10b5-1
$175.6K
6.3K sh · $27.66
Own -8%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
4.2K sh
Own +5%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
3.5K sh
Own +3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
6.3K sh
Own +50%
-
Sell·S
Chief Medical Officer · 10b5-1
$373.1K
14.1K sh · $26.54
Own -16%
-
Exercise·M
Chief Medical Officer · 10b5-1
$59.4K
4.2K sh · $14.25
Own +5%
-
Exercise·M
Chief Medical Officer · 10b5-1
$36.1K
3.5K sh · $10.20
Own +4%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.9K
6.3K sh · $1.08
Own +8%
-
Sell·S
Jon Congleton KEY
Chief Executive Officer · 10b5-1
$422.0K
15.7K sh · $26.83
Own -2%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
2.2K sh
Own +11%
-
Sell·S
Chief Medical Officer · 10b5-1
$59.4K
2.2K sh · $27.38
Own -3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$34.7K
2.2K sh · $16.00
Own +3%
-
Exercise·M
Director · 10b5-1
$0
3.0K sh
Own +8%
-
Sell·S
Director · 10b5-1
$75.0K
3.0K sh · $25.00
Own -33%
-
Exercise·M
Director · 10b5-1
$36.1K
3.0K sh · $12.02
Own +48%
-
Sell·S
Jon Congleton KEY
Chief Executive Officer · 10b5-1
$12.3K
453 sh · $27.05
Own -0%
-
Sell·S
Jon Congleton KEY
Chief Executive Officer · 10b5-1
$1.5M
55.2K sh · $26.54
Own -7%
-
Sell·S
Jon Congleton KEY
Chief Executive Officer · 10b5-1
$493.8K
19.4K sh · $25.50
Own -2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 417 | $0 |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $0 |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Sell S | 4.6K | $114.6K |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 417 | $6.4K |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $59.4K |
| Jun 17, 2026 | Daphne Karydas 10b5-1 | Exercise M | 3.0K | $0 |
| Jun 17, 2026 | Daphne Karydas 10b5-1 | Sell S | 3.0K | $75.0K |
| Jun 17, 2026 | Daphne Karydas 10b5-1 | Exercise M | 3.0K | $36.1K |
| Jun 15, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $0 |
| Jun 15, 2026 | David Malcom Rodman 10b5-1 | Sell S | 9.9K | $235.5K |
| Jun 15, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $36.1K |
| Jun 12, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $0 |
| Jun 12, 2026 | David Malcom Rodman 10b5-1 | Sell S | 6.3K | $151.9K |
| Jun 12, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $6.9K |
| Jun 10, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $0 |
| Jun 10, 2026 | David Malcom Rodman 10b5-1 | Sell S | 2.2K | $54.2K |
| Jun 10, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $34.7K |
| May 18, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 417 | $0 |
| May 18, 2026 | David Malcom Rodman 10b5-1 | Sell S | 417 | $11.5K |
| May 18, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 417 | $6.4K |
| May 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $0 |
| May 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $0 |
| May 13, 2026 | David Malcom Rodman 10b5-1 | Sell S | 14.1K | $401.8K |
| May 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $59.4K |
| May 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $36.1K |
| May 12, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $0 |
| May 12, 2026 | David Malcom Rodman 10b5-1 | Sell S | 6.3K | $186.3K |
| May 12, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $6.9K |
| May 11, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $0 |
| May 11, 2026 | David Malcom Rodman 10b5-1 | Sell S | 2.2K | $64.5K |
| May 11, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $34.7K |
| Apr 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 416 | $0 |
| Apr 17, 2026 | David Malcom Rodman 10b5-1 | Sell S | 416 | $13.0K |
| Apr 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 416 | $6.4K |
| Apr 15, 2026 | David Malcom Rodman 10b5-1 | Sell S | 6.3K | $175.6K |
| Apr 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $0 |
| Apr 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $0 |
| Apr 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $0 |
| Apr 13, 2026 | David Malcom Rodman 10b5-1 | Sell S | 14.1K | $373.1K |
| Apr 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $59.4K |
| Apr 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $36.1K |
| Apr 13, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $6.9K |
| Apr 13, 2026 | Jon Congleton KEY 10b5-1 | Sell S | 15.7K | $422.0K |
| Apr 9, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $0 |
| Apr 9, 2026 | David Malcom Rodman 10b5-1 | Sell S | 2.2K | $59.4K |
| Apr 9, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $34.7K |
| Mar 31, 2026 | Daphne Karydas 10b5-1 | Exercise M | 3.0K | $0 |
| Mar 31, 2026 | Daphne Karydas 10b5-1 | Sell S | 3.0K | $75.0K |
| Mar 31, 2026 | Daphne Karydas 10b5-1 | Exercise M | 3.0K | $36.1K |
| Mar 31, 2026 | Jon Congleton KEY 10b5-1 | Sell S | 453 | $12.3K |
| Mar 31, 2026 | Jon Congleton KEY 10b5-1 | Sell S | 55.2K | $1.5M |
| Mar 31, 2026 | Jon Congleton KEY 10b5-1 | Sell S | 19.4K | $493.8K |
About MLYS insider trading
This page tracks insider transactions for Mineralys Therapeutics, Inc. (MLYS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.